What We May Expect from Biomarkers in Heart Failure

Braunwald, 2008, Biomarkers in heart failure, N Engl J Med, 358, 2148, 10.1056/NEJMra0800239 Morrow, 2007, Benchmarks for the assessment of novel cardiovascular biomarkers, Circulation, 115, 949, 10.1161/CIRCULATIONAHA.106.683110 Richards, 2003, B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction, Circulation, 107, 2786, 10.1161/01.CIR.0000070953.76250.B9 Latini, 2004, The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT, Eur Heart J, 25, 292, 10.1016/j.ehj.2003.10.030 Kiowski, 1995, Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure, Lancet, 346, 732, 10.1016/S0140-6736(95)91504-4 Rademaker, 1997, Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure, Circulation, 96, 1983, 10.1161/01.CIR.96.6.1983 Rademaker, 2005, Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure, Eur Heart J, 26, 2046, 10.1093/eurheartj/ehi227 Vasan, 2003, Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study, Circulation, 107, 1486, 10.1161/01.CIR.0000057810.48709.F6 Levine, 1990, Elevated circulating levels of tumor necrosis factor in severe chronic heart failure, N Engl J Med, 223, 236, 10.1056/NEJM199007263230405 Rauchhaus, 2000, Plasma cytokine parameters and mortality in patients with chronic heart failure, Circulation, 102, 3060, 10.1161/01.CIR.102.25.3060 Anker, 2004, Inflammatory mediators in chronic heart failure: an overview, Heart, 90, 464, 10.1136/hrt.2002.007005 Spinale, 1999, Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function, Circ Res, 85, 364, 10.1161/01.RES.85.4.364 Horwich, 2003, Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure, Circulation, 108, 833, 10.1161/01.CIR.0000084543.79097.34 Weinberg, 2003, Identification of serum soluble ST2 receptor as a novel heart failure biomarker, Circulation, 107, 721, 10.1161/01.CIR.0000047274.66749.FE Januzzi, 2007, Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study, J Am Coll Cardiol, 50, 607, 10.1016/j.jacc.2007.05.014 Molyneux, 2008, Coenzyme Q10: an independent predictor of mortality in chronic heart failure, J Am Coll Cardiol, 52, 1435, 10.1016/j.jacc.2008.07.044 Kempf, 2007, Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure, J Am Coll Cardiol, 50, 1054, 10.1016/j.jacc.2007.04.091 van Kimmenade, 2006, Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure, J Am Coll Cardiol, 48, 1217, 10.1016/j.jacc.2006.03.061 Omland, 2007, Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function, Hypertension, 49, 1392, 10.1161/HYPERTENSIONAHA.107.087742 Richards, 2004, Urotensin II in the cardiovascular system, Peptides, 25, 1795, 10.1016/j.peptides.2004.04.017 Troughton, 2008, Outpatient monitoring and treatment of chronic heart failure guided by NT-proBNP measurement, Am J Cardiol, 101, 72A, 10.1016/j.amjcard.2007.11.027 Francis, 1993, Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II, Circulation, 87, VI40 Zannad, 2000, Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES), Circulation, 102, 2700, 10.1161/01.CIR.102.22.2700 Richards, 1999, Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction, Circulation, 99, 786, 10.1161/01.CIR.99.6.786 1987, The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N Engl J Med, 316, 1429, 10.1056/NEJM198706043162301 Goldstein, 2001, Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study, J Am Coll Cardiol, 38, 932, 10.1016/S0735-1097(01)01516-9 Publication Committee for the VI, 2002, Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial, JAMA, 287, 1531, 10.1001/jama.287.12.1531 Swedberg, 2002, Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure, Circulation, 105, 1797, 10.1161/01.CIR.0000014212.04920.62 Mann, 2004, Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL), Circulation, 109, 1594, 10.1161/01.CIR.0000124490.27666.B2 Kelland, 2007, Clinical trials of endothelin antagonists in heart failure: publication is good for the public health, Heart, 93, 2, 10.1136/hrt.2006.089250 Konstam, 2007, Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial, JAMA, 297, 1319, 10.1001/jama.297.12.1319 Arab, 2006, Cardiovascular proteomics: tools to develop novel biomarkers and potential applications, J Am Coll Cardiol, 48, 1733, 10.1016/j.jacc.2006.06.063 Lewis, 2008, Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury, J Clin Invest, 118, 3503, 10.1172/JCI35111